Online inquiry

IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13068MR)

This product GTTS-WQ13068MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MADCAM1 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_130760.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8174
UniProt ID Q13477
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13068MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9748MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA JR-141
GTTS-WQ9794MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA JS002
GTTS-WQ8357MR IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA hPAM4
GTTS-WQ9123MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMGN242
GTTS-WQ2311MR IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALXN-1210
GTTS-WQ2566MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 479
GTTS-WQ14433MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ698MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA A-1230717
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW